crucial. In this era of biologic therapies, misdiagnosis, and the use of inappropriate drugs in CTCL may lead to catastrophic outcomes. If dupilumab had a role in progression or histopathological presentation is unknown. More studies are needed, and a more accurate and careful indication of biologic therapies is imperative. CONFLICT OF INTEREST The authors declare no conflicts of interest. AUTHOR CONTRIBUTIONS Denis Miyashiro designed the research, gathered and analyzed the data, and wrote the majority of the manuscript. Ana Gabriela Vivarelli gathered and analyzed the data and wrote part of the manuscript. Fernanda Gonçalves gathered and analyzed the data and wrote part of the manuscript. Jade Cury-Martins analyzed the data. José Antonio Sanches designed the research, analyzed the data, and wrote part of the manuscript. All authors have read and approved the submitted version of the manuscript.